Trametinib-mediated MEK inhibition impairs cancer cell viability and invasion in patient-derived tumor avatars of glioblastoma with extraneural metastases: A proof-of-concept study.
Metka Novak, Bernarda Majc, Marija Skoblar Vidmar et al.
✦ AI-curated · Sources linked
Case in brief
A patient with glioblastoma (GBM) presented with rare extraneural metastases, characterized by aggressive molecular features including alterations in NF1, TP53, PTEN, and RB1. Patient-derived tumor models were developed, revealing that the MEK inhibitor trametinib effectively reduced cell viability and invasion in these models. This case suggests a potential targeted treatment strategy for metastatic GBM.
Diagnostic / clinical pearl
Clinicians should consider the potential of targeted therapies like MEK inhibitors in managing aggressive metastatic glioblastoma, particularly in cases with specific molecular alterations.
Why it matters
This case emphasizes the importance of personalized treatment approaches in glioblastoma, highlighting the need for ongoing research into targeted therapies for improved patient outcomes.